Portal de investigación
Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Delgado-Jimenez, Juan F.
- Segovia-Cubero, Javier
- de Juan-Baguda, Javier
- Lara-Padron, Antonio
- Garcia-Pinilla, Jose Manuel
- Bonilla-Palomas, Juan Luis
- Lopez-Fernandez, Silvia
- Mirabet-Perez, Sonia
- Gomez-Otero, Ines
- Castro-Fernandez, Antonio
- Diaz-Molina, Beatriz
- Goirigolzarri-Artaza, Josebe
- Rincon-Diaz, Luis Miguel
- Pascual-Figal, Domingo Andres
- Anguita-Sanchez, Manuel
- Muñiz J
- Crespo-Leiro, Maria G.
Grupos
Abstract
Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a negative impact on prognosis. The objective of the present study was to estimate the prevalence of hyperkalaemia in outpatients with HFrEF and its impact on achieving optimal medical treatment. For this purpose, a multicentre, prospective, and observational study was carried out on consecutive HFrEF patients who were monitored as outpatients in heart failure (HF) units and who, in the opinion of their doctor, received optimal medical treatment. A total of 565 HFrEF patients were included from 16 specialised HF units. The mean age was 66 ± 12 years, 78% were male, 45% had an ischemic cause, 39% had atrial fibrillation, 43% were diabetic, 42% had a glomerular filtration rate < 60 mL/min/1.7 m 2 , and the mean left ventricular ejection fraction was 31 ± 7%. Treatment at the study entry included: 76% on diuretics, 13% on ivabradine, 7% on digoxin, 18.9% on angiotensin-conversing enzyme inhibitors (ACEi), 11.3% on angiotensin receptors blockers (ARBs), 63.8% on angiotensin-neprilysin inhibitors (ARNi), 78.5% on mineralocorticoid receptor antagonists (MRAs), and 92.9% on beta-blockers. Potassium levels in the baseline analysis were: =5 mEq/L = 80.5%, 5.1-5.4 mEq/L = 13.8%, 5.5-5.9 mEq/L = 4.6%, and =6 mEq/L = 1.06%. Hyperkalaemia was the reason for not prescribing or reaching the target dose of an MRAs in 34.8% and 12.5% of patients, respectively. The impact of hyperkalaemia on not prescribing or dropping below the target dose in relation to ACEi, ARBs, and ARNi was significantly less. In conclusion, hyperkalaemia is a frequent problem in the management of patients with HFrEF and a limiting factor in the optimisation of medical treatment.
Datos de la publicación
- ISSN/ISSNe:
- 2077-0383, 2077-0383
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/jcm11051170
- PubMed:
- 35268260
- Factor de Impacto:
- 1,040 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Journal of Clinical Medicine MDPI
Citas Recibidas en Web of Science: 3
Documentos
- No hay documentos
Filiaciones
Keywords
- heart failure, hyperkalaemia, medical treatment
Campos de Estudio
Cita
Delgado JF,Segovia J,ALMENAR L,de Juan J,Lara A,Garcia JM,Bonilla JL,Lopez S,Mirabet S,Gomez I,Castro A,Diaz B,Goirigolzarri J,Rincon LM,Pascual DA,Anguita M,Muñiz J,Crespo MG. Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics. J. Clin. Med. 2022. 11. (5):1170. IF:3,900. (2).